These findings suggest that Andrographolide not only modulates VAT-specific metabolism but also exerts beneficial effects on whole-body glucose homeostasis in APP/PS1 mice with obesity, thereby contributing to an overall improvement in metabolic health. Here, APP is linked to obesity due to melanocortin 4 receptor deficiency.